Antimicrobial Susceptibility, Mycobacterium tuberculosis Complex, First Line, Varies
Use
Susceptibility testing of Mycobacterium tuberculosis complex isolates is crucial for determining the appropriate antimicrobial therapy. It guides the treatment of tuberculosis by identifying resistance to first-line antimycobacterial agents such as isoniazid, rifampin, and ethambutol. This testing is essential for patient management and helps prevent the use of ineffective treatments, thereby reducing the spread of resistant strains.
Special Instructions
Specimen source and suspected organism identification are required. If the organism identification is not provided, additional culture tests like CTB or CTBID must also be ordered and will be charged separately. Shipping guidelines should be followed strictly to ensure safe and proper transport of specimens.
Limitations
The test requires isolates in pure culture for accurate results. Isolates not received in pure culture may cause delays as isolation is needed before testing. This test does not include susceptibility testing for the first-line agent pyrazinamide, which requires separate sequencing tests. Interpretation of results should be guided by specialists due to the complexity of resistance patterns.
FDA ApprovedNew York Approved
Methodology
Culture-based
Biomarkers
LOINC Codes
- 29579-0
- 29579-0
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Other
Volume
Isolate
Minimum Volume
Not provided
Container
Middlebrook 7H10 agar slant
Collection Instructions
Organism must be in pure culture, actively growing.
Causes for Rejection
Agar plate